AC Immune (ACIU) Equity Average (2015 - 2025)

AC Immune (ACIU) has 10 years of Equity Average data on file, last reported at $67.1 million in Q4 2025.

• Quarterly Equity Average fell 51.79% year-over-year to $67.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $67.1 million (down 51.79% YoY) and the FY2025 annual result came in at $91.1 million, down 41.05% from the prior year.
• Equity Average slipped to $67.1 million in Q4 2025 per ACIU's latest filing, from $84.2 million in the prior quarter.
• Across five years, Equity Average topped out at $218.5 billion in Q2 2021 and bottomed at $67.1 million in Q4 2025.
• The 5-year median for Equity Average is $166.0 million (2023), against an average of $31.7 billion.
• The widest annual swing landed in 2021, when Equity Average soared 81589.78%; it then tumbled 99.9% in 2022.
• Tracing ACIU's Equity Average over 5 years: stood at $97.7 billion in 2021, then slumped by 99.81% to $186.1 million in 2022, then dropped by 13.12% to $161.7 million in 2023, then retreated by 13.91% to $139.2 million in 2024, then sank by 51.79% to $67.1 million in 2025.
• Per Business Quant, the three latest ACIU Equity Average figures stand at $67.1 million (Q4 2025), $84.2 million (Q3 2025), and $97.9 million (Q2 2025).

Peer Comparison